Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06851975
Recruiting Observational

Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

NCT06851975 · tracked via the Priya Life Science France tracker
Sponsor
Centre Antoine Lacassagne
Phase
Observational
Started
2020-01-07
Last updated
2026-05-29

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

blood sampling

blood sampling: 36ml of blood will be taken during a blood sampling performed in standard practice

Study summary

Research into biomarkers predictive of survival and response to cancer treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care, * Patient who has read the information note and stated that he/she has no objections * Patient who has not objected to the use of this data for medical research purposes * Patient with social security cover. Exclusion Criteria: * Patient already included in the study * Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Antoine Lacassagne Nice France Recruiting

More Centre Antoine Lacassagne trials in France

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma Recruiting
Study of the Impact of DPD Activity on the Efficacy of Capecitabine Active, not recruiting
Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy Recruiting
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma Recruiting
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma Active, not recruiting

Other trials for the same condition

Study of IMC-P115C in Advanced PRAME-Positive Cancers Recruiting
Efficacy Study on Quality of Life Criteria of a Digital Application on Any Cellphone (OnKO-Tips&Tricks) for Adolescents and Young Adults Diagnosed With Cancer Active, not recruiting
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs Active, not recruiting
Met Non Small Cell Cancer Registry (MOMENT) Recruiting
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06851975 on ClinicalTrials.gov ↗ ← All trials in France